Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This small, double-blind pilot trial gave 28 people with alcohol problems either a sublingual esketamine film (115.1 mg) or a vitamin C placebo while they did two weeks of daily mindfulness practice. Compared with placebo, esketamine increased people’s psychological engagement with the meditation, produced stronger mystical and dissociative experiences, and…
We provide further preliminary evidence for the efficacy and tolerability of IM ketamine in an outpatient cohort of OCD. Additional work is required to establish the optimal dosing regimen and longer-term role of ketamine for OCD. These findings are encouraging given the well-known limitations that exist for treatments in this…
In 14 people with opioid use disorder who each received a single 10 mg/kg dose of ibogaine, researchers measured blood levels of ibogaine and its metabolites over 24 hours and linked those levels to side effects. They found large differences between people in how fast ibogaine was cleared, and that…
This retrospective study looked at 117 outpatients with high PTSD Checklist (PCL-5) scores who received at least six intravenous ketamine sessions given in a supportive, “psychedelic” style (preparation, intention-setting, eye shades, evocative music, and integration). Average PCL-5 scores fell from 52.54 (SD = 12.01) to 28.78 (SD = 16.61), a…
